The strong EPS beat and raised guidance confirm improving margins and operational leverage. However, unchanged revenue guidance and modest organic growth (2.9% organic constant currency) suggest limited top-line acceleration. Watch for margin expansion and share repurchase execution to drive further EPS upside.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 28 $82.45entry
- T+1 · 7mo ago −2.92%α −2.91% · $80.04
- T+5 · 7mo ago +0.22%α −1.47% · $82.63
- T+20 · 6mo ago +0.08%α −5.37% · $82.52
- T+60 · 4mo ago +8.74%α +5.02% · $89.65
Price Chart
How similar events traded
Executive Summary
Zimmer Biomet reported Q1 2026 adjusted EPS of $2.09, beating consensus of $1.86 by 12.4%, on revenue of $2.087B (+9.3% YoY reported). The company raised its full-year adjusted EPS guidance to $8.40-$8.55 from $8.30-$8.45, while maintaining revenue growth guidance of 2.5%-4.5% reported. The results reflect solid operational execution and ongoing share repurchases.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $2.087B, up 9.3% reported vs Q1 2025
- Adjusted diluted EPS of $2.09, up 15.5% YoY and 12.4% above consensus $1.86
- GAAP diluted EPS of $1.22, up 34.1% YoY
- Full-year 2026 adjusted EPS guidance raised to $8.40-$8.55 (prior $8.30-$8.45)
- Revenue guidance unchanged: reported change 2.5%-4.5%, organic constant currency 1.0%-3.0%
- Operating cash flow of $359M, free cash flow of $246M in Q1
- Repurchased $250M of shares during Q1 2026
Financial Impact
Adjusted EPS beat consensus by $0.23 (12.4%), and full-year EPS guidance midpoint increased by $0.10
Risk Factors
- Revenue guidance unchanged, indicating cautious top-line outlook
- Goodwill impairment assessment still pending (not booked in Q1)
- Go-to-market transformation may create near-term disruption
- Tariff headwinds and integration of Paragon 28 remain risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-183411 |
| Document: zbh-20260428.htm | 0001193125-26-183411 |
| Document: 0001193125-26-183411-index-headers.html | 0001193125-26-183411 |
| Document: 0001193125-26-183411-index.html | 0001193125-26-183411 |
| Document: 0001193125-26-183411.txt | 0001193125-26-183411 |
| 8-K Data (Synthetic) | 0001193125-26-183411 |
Track record
17 reports on ZBH
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +3.00% at T+5 after the Oct 26, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $103.21 Now $101.41 −1.74% settles Nov 20
- Nov 9, 20267d ago 424B5 Neutral 3/10 Entry $107.32 Now $101.41 −5.51% settles Nov 17
- Nov 9, 20267d ago 424B5 Neutral 3/10 Entry $107.32 Now $101.41 −5.51% settles Nov 17
- Nov 5, 202611d ago 424B5 Neutral 3/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
- Nov 5, 202611d ago 424B5 Neutral 2/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $110.15 to $107.47 Now $101.41 −7.93% ▼ −2.43% −1.52% vs SPY
- Oct 26, 202621d ago Institutional Cluster Bearish 4/10 Entry $97.44 to $94.52 Now $101.41 −4.07% ▲ +3.00% +1.74% vs SPY
- Oct 21, 202627d ago Court Ruling Bearish 6/10 Entry $98.81 to $97.47 Now $101.41 −2.63% ▲ +1.36% +2.06% vs SPY
- Sep 15, 20268w ago Insider Cluster Neutral 3/10 Entry $96.53 to $90.64 Now $101.41 +5.06% ▼ −6.10% −8.17% vs SPY
- Sep 2, 202610w ago Court Ruling Neutral 2/10 Entry $98.66 to $93.24 Now $101.41 +2.79% ▼ −5.49% −4.34% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers